Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04968210 · ClinicalTrials.gov registry record
Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH)
A clinical trial, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- 3
- Enrollment target
NCT04968210: Completed study, sponsored by University of Texas Southwestern Medical Center.
NCT04968210 is a clinical trial that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04968210 has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- 3 participants
- Enrollment target
Study Summary
Pulmonary arterial hypertension (PAH) is a progressive disease in which clinically relevant symptoms present a few years after the onset in rise of pulmonary arterial pressure. Increased PA pressure presents an overload on the right ventricle (RV), with RV failure being a common cause of mortality in PAH. Current therapeutic targets help reduce vascular resistance and RV afterload, however, RV dysfunction may continue to progress. Therefore, the reason for RV failure in PAH cannot be contributed to altered vascular hemodynamics alone but may be related to metabolic alterations and failure of adaptive mechanisms in the RV. Providing a better understanding of metabolic remodeling in RV failure may permit the development of RV-targeted pharmacological agents to maintain RV function despite increased pulmonary vascular pressures. This study will evaluate how cardiac metabolism changes in response to pulmonary vasodilator therapy in patients with pulmonary arterial hypertension.
Primary Outcome
Ratio of bicarbonate to lactate area under the curve, as a measure of oxidative metabolism relative to glycolysis, respectively. The ratio will be compared before and after 6 months of standard of care pulmonary vasodilator therapy in PAH patients.
Interventions
- DRUG Hyperpolarized 13C-pyruvate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2024-12-17 |
What the finished NCT04968210 record still lists
NCT04968210 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 3 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Hyperpolarized 13C-pyruvate is the first listed.
NCT04968210 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04968210 about?
NCT04968210 is a clinical study titled "Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH)". Pulmonary arterial hypertension (PAH) is a progressive disease in which clinically relevant symptoms present a few years after the onset in rise of pulmonary arterial pressure. Increased PA pressure presents an overload on the right ventricle (RV), with RV failure being a common cause of mortality i...
What is the current status of trial NCT04968210?
This trial is currently completed. The enrollment target is 3 participants. The study started on 2022-05-27. Estimated completion is 2024-12-17.
What interventions are being tested in trial NCT04968210?
The interventions under investigation include: Hyperpolarized 13C-pyruvate (DRUG).
Who is sponsoring clinical trial NCT04968210?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI